Abstract:Objective To study the burden of pediatric cancer in Jiangxi, China, in 2010 and 2015 and its changes from 2010 to 2015.Methods The data of pediatric cancer in Jiangxi in 2010 and 2015 were collected from the Global Burden of Disease Study 2015 in China, including number of cases, number of deaths, years of life lost (YLL), years lived with disability (YLD), and disability-adjusted life years (DALY). The standardized incidence rate, mortality rate, and DALY rate were calculated with the national census data in 2010 as the standard population, in order to evaluate the changes in incidence, mortality, and disease burden of pediatric cancer in Jiangxi.Results In both 2010 and 2015, boys had higher numbers of cases, deaths, and DALY than girls, and the 5-14 years group had higher numbers than the 0-4 years group; boys had higher incidence rate, mortality rate, and DALY rate than girls, and the 0-4 years group had higher rates than the 5-14 years group. In 2015, the standardized incidence rate of pediatric cancer was reduced by 6.66% in the 0-4 years group and 17.56% in the 5-14 years group; the standardized mortality rate was reduced by 11.34% in the 0-4 years group and 21.78% in the 5-14 years group; the standardized DALY rate was reduced by 11.27% in the 0-4 years group and 21.67% in the 5-14 years group. Among the different types of pediatric cancer, leukemia had the highest standardized DALY rate in 2010 and 2015, followed by brain cancer and non-Hodgkin's lymphoma.Conclusions There was a certain reduction in the burden of pediatric cancer in Jiangxi from 2010 to 2015. Leukemia, brain cancer, and non-Hodgkin's lymphoma are the focus of prevention and treatment, and children aged less than 5 years and boys should be closely monitored.
Naghavi M, Makela S, Foreman K, et al. Algorithms for enhancing public health utility of national causes-of-death data[J]. Popul Health Metr, 2010, 8:9.
[4]
Ahern RM, Lozano R, Naghavi M, et al. Improving the public health utility of global cardiovascular mortality data:the rise of ischemic heart disease[J]. Popul Health Metr, 2011, 9:8.
[5]
GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015:a systematic analysis for the Global Burden of Disease Study 2015[J]. Lancet, 2016, 388(10053):1545-1602.
[6]
GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015:a systematic analysis for the Global Burden of Disease Study 2015[J]. Lancet, 2016, 388(10053):1459-1544.
[7]
GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015:a systematic analysis for the Global Burden of Disease Study 2015[J]. Lancet, 2016, 388(10053):1603-1658.
GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013:a systematic analysis for the Global Burden of Disease Study 2013[J]. Lancet, 2015, 380(9963):117-171.
Ang JP, Heath JA, Donath S, et al. Treatment outcomes for hepato-blastoma:an institution's experience over two decades[J]. Pediatr Surg Int, 2007, 23(2):103-109.